Skip to main content
. 2021 Nov 19;54(4):996–1004. doi: 10.4143/crt.2021.902

Table 3.

Multivariable analysis for the illness-death model based on the Akaike information criterion in patients with lung cancer

Variable Relapse Death without relapse Death after relapse



HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age (yr) 1.02 (1.00–1.04) 0.115 1.07 (1.03–1.11) < 0.001 - -

Former or current smoker - - 4.05 (1.95–8.39) < 0.001 - -

History of malignancy other than lung cancer 1.67 (1.07–2.6) 0.023 - - - -

Location at a lower lobe 0.63 (0.44–0.89) 0.009 1.97 (1.17–3.32) 0.011 - -

Pneumonectomy (reference: lobectomy) 1.97 (1.20–3.23) 0.007 2.58 (1.26–5.28) 0.009 1.84 (1.03–3.28) 0.039

TNM stage (reference: 1A)

 1B 1.19 (0.58–2.42) 0.632 2.42 (1.1–5.32) 0.027 - -

 2A 2.98 (1.32–6.73) 0.009 2.30 (0.71–7.44) 0.164 - -

 2B 3.55 (1.80–7.01) < 0.001 3.16 (1.38–7.23) 0.007 - -

 3A 5.26 (2.61–10.59) < 0.001 11.20 (4.61–27.21) < 0.001 - -

 3B or 3C 12.06 (5.35–27.22) < 0.001 16.35 (5.47–48.91) < 0.001 - -

Interaction of cancer type and treatment (reference: SqCC and operation only)

 SqCC and adjuvant therapy 0.62 (0.29–1.32) 0.214 0.10 (0.05–0.23) < 0.001 - -

 ADC and operation only 0.44 (0.21–0.92) 0.029 0.44 (0.22–0.89) 0.022 0.52 (0.33–0.83)a) 0.006

 ADC and adjuvant therapy 1.65 (0.83–3.28) 0.157 0.17 (0.07–0.40) < 0.001

ADC, adenocarcinoma; Adjuvant therapy, adjuvant chemo- or radiation therapy; CI, confidence interval; HR, hazard ratio, SqCC, squamous cell carcinoma.

a)

HR of ADC relative to SqCC, ignoring treatment.